HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Revised PAL to Embrace “Deeper” Safety Measures, Yet Also Escape Clauses to Ease Company Burdens

Lexicon

Drug requiring guidance:
要指導医薬品

The Column

Successful People Have the Best Information

Archives

AZ Was Concerned with Pfizer’s Possible Takeover Deal Withdrawal Due to US Anti-Inversion Move: CEO(Sep.30)
e-Detailing Powerhouse M3 to Establish New Firm Dedicated to CSO Biz(Sep.30)
Lixiana OK’d for Stroke Prevention in Japan: Daiichi Sankyo(Sep.30)
Daiichi Sankyo to Buy US Biotech Ambit, Beef Up Oncology Portfolio(Sep.30)
Kyowa Kirin’s Neutropenia Treatment G-Lasta Approved(Sep.30)

Most Read

1.
Editor’s Pick: ...
2.
MHLW Approves A...
3.
Daclatasvir/Asu...
4.
Takeda to Inves...
5.
Govt Panel Appr...

News Calendar